Retro Screening¶
Hold a compound query fixed, compare it across many target-associated representations, and prioritize putative biological targets for separate testing.
Core Idea¶
Retro screening searches for possible biological targets of a compound. It holds that compound, or a defined small query set, fixed and compares it across representations linked to many candidate targets. The output prioritizes target hypotheses for separate testing. It does not prove that every hit binds, causes an adverse effect or works as a treatment.[ref-e1c07e749e9b][ref-6556d7bf20e2]
The target-side representation can vary. Rollinger and colleagues compared plant compounds against a large pharmacophore-model collection, including ligand-derived models. Keiser and colleagues compared existing drugs with sets of ligands known to act on many targets. Both use the compound-to-many-target direction without requiring a protein crystal structure for every target.[ref-e1c07e749e9b][ref-6556d7bf20e2]
Scope of Application¶
In the Ruta graveolens study, 16 isolated compounds were separately screened against 2,208 pharmacophore models covering more than 280 targets. Rutamarin matched a ligand-derived CB2-receptor model; a later radioligand assay found moderate selective binding in a small tested subset. Receptor agonism versus antagonism remained open.[^ref-e1c07e749e9b]
In the existing-drug study, 3,665 approved or investigational drugs were compared with ligand sets for hundreds of targets. The authors experimentally tested 30 predicted associations and reported 23 confirmed, including fluoxetine/Prozac antagonism at the beta1 adrenergic receptor. That result does not by itself explain a clinical side effect or prove a new therapeutic indication.[^ref-6556d7bf20e2]
Clarity¶
Name the query compound, target-indexed collection, comparison rule, candidate associations and follow-up evidence. A protein structure is optional: ligand sets and pharmacophores can represent targets. A computational similarity or fit score is a prediction, whereas an assay supplies different evidence. A study may test only a selected subset of its virtual hits.[ref-e1c07e749e9b][ref-6556d7bf20e2]
Manages Complexity¶
A single compound can have many plausible target associations. Retro screening organizes this search by holding the query side fixed and comparing it with many target-side representations, then reducing the result to candidates for costly follow-up. The Ruta work narrows a large pharmacophore search to selected assays; the Keiser work uses chemical similarity to select unexpected drug–target associations for testing.[ref-e1c07e749e9b][ref-6556d7bf20e2]
Abstract Reasoning¶
Start with a compound whose target profile is uncertain. Choose a collection in which each candidate target is represented by relevant binding-site, pharmacophore or ligand evidence. Compare the query across target entries using a stated method, prioritize hypotheses, and test any biological claim separately. If instead one protein is held fixed while many ligands vary, the procedure is forward screening. A single preselected compound–target comparison is not a target-panel search.[ref-e1c07e749e9b][ref-6556d7bf20e2]
Knowledge Transfer¶
The reusable map is compound query → many target representations → comparison → provisional target ranking → separate validation. The two studies fill target representations and score rules differently, so their scores should not be treated as interchangeable. The live Search and Retrieval Prime is the broader query-to-candidate matching process; compound chemistry and biological evidence limits make this a domain-specific subtype.[ref-e1c07e749e9b][ref-6556d7bf20e2]
Example¶
Plant-compound target fishing. Rutamarin, one of 16 Ruta constituents screened by Rollinger and colleagues, matched a ligand-derived CB2 pharmacophore among a large target-model collection. Query → rutamarin; collection → 2,208 target-associated models; comparison → conformer-to-pharmacophore fit; output → tentative CB2 association; separate test → moderate selective CB2 binding in a small assay subset, with receptor function unresolved.[^ref-e1c07e749e9b]
Existing-drug off-target search. Keiser and colleagues compared each drug with target-defining ligand sets. Query → a drug such as fluoxetine; collection → ligand sets for hundreds of proteins; comparison → method-specific chemical similarity; output → unexpected candidates including beta1 receptor; separate test → selected pharmacological assays, not a blanket confirmation of all predictions or clinical outcomes.[^ref-6556d7bf20e2]
Relationships to Other Abstractions¶
Current abstraction Retro Screening Domain-specific
Parents (1) — more general patterns this builds on
-
Retro Screening is a kind of Search and Retrieval Prime
A compound query searches a represented target collection and retrieves prioritized candidate target associations.
Hierarchy paths (4) — routes to 3 parentless roots
- Retro Screening → Search and Retrieval → Problem Space → Representation → Abstraction
- Retro Screening → Search and Retrieval → Trade-offs → Constraint
- Retro Screening → Search and Retrieval → Problem Space → State and State Transition → Phase Space
- Retro Screening → Search and Retrieval → Problem Space → Problem Representation → Representation → Abstraction
Neighborhood in Abstraction Space¶
Retro Screening sits in a sparse region of the domain-specific corpus (97th percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.
Family — Protein Structure Prediction & Folding (7 abstractions)
Nearest neighbors
- Substructure Search — 0.82
- Lipinski's Rule of Five — 0.77
- Searching the conformational space for docking — 0.76
- Structural Formula — 0.76
- Epitope mapping — 0.76
Computed from structural-signature embeddings · 2026-10-08
Not to Be Confused With¶
Forward virtual screening: one target is fixed while many compounds vary. Pairwise docking: a target-panel search has not occurred. Empirical binding or clinical efficacy: these require separate tests. Mandatory protein structures: ligand-derived target representations are attested. Universal score correction: calibration is method-specific. The live Screening Prime: it concerns economic self-selection, a different mechanism.[ref-e1c07e749e9b][ref-6556d7bf20e2]
References¶
[^ref-e1c07e749e9b]: J. M. Rollinger, D. Schuster, B. Danzl et al., “In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens”, Planta Medica 75 (2009): 195–204, DOI 10.1055/s-0028-1088397, Methods “Pharmacophore modelling” and “Parallel screening”; Results “Target fishing” and “CB2”, Tables 4–5. Original author manuscript of the published paper; the small CB2 test set cannot support a general predictive-accuracy estimate.
[^ref-6556d7bf20e2]: M. J. Keiser, V. Setola, J. J. Irwin et al., “Predicting new molecular targets for known drugs”, Nature 462 (2009): 175–181, DOI 10.1038/nature08506, abstract, methods, Fig. 2 and Results. Original author manuscript of the published paper; drug-to-target-ligand-set comparison, selected tests and confirmed associations. Clinical side effects or new treatment efficacy are possibilities for later work, not established by the screen alone.